Biotest GmbH & Co. KGaA (HAM:BIO0)
Germany · Delayed Price · Currency is EUR 33.00
0.00 (0.00%)
At close: Jul 2, 2026
Biotest GmbH & Co. KGaA Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 648.9 | 726.2 | 684.6 | 516.1 | 515.6 | |
Revenue Growth (YoY) | -10.64% | 6.08% | 32.65% | 0.10% | 6.49% |
Cost of Revenue | 579.4 | 502.4 | 404.3 | 391.2 | 434.9 |
Gross Profit | 69.5 | 223.8 | 280.3 | 124.9 | 80.7 |
Selling, General & Admin | 82.5 | 91.3 | 84.4 | 81.9 | 82 |
Research & Development | 66.7 | 56.8 | 66.8 | 50.5 | 52.3 |
Other Operating Expenses | -27.2 | -3.2 | 12.5 | 12.7 | -2.7 |
Operating Expenses | 126 | 137 | 163.6 | 145.1 | 131.6 |
Operating Income | -56.5 | 86.8 | 116.7 | -20.2 | -50.9 |
Interest Expense | -34.4 | -30.3 | -36.6 | -18.5 | -12.4 |
Interest & Investment Income | 1.7 | 2 | 2 | 0.8 | 0.2 |
Earnings From Equity Investments | - | -4.4 | 2.8 | -1 | 1.3 |
Currency Exchange Gain (Loss) | -0.5 | -1.1 | -0.8 | 0.2 | -0.4 |
Other Non Operating Income (Expenses) | -5.8 | -1.4 | -0.3 | -2.9 | -2.3 |
EBT Excluding Unusual Items | -95.5 | 51.6 | 83.8 | -41.6 | -64.5 |
Gain (Loss) on Sale of Investments | - | -9.7 | -0.9 | 8.4 | -1.2 |
Other Unusual Items | 0.9 | 3.8 | 23.2 | 1.1 | 1.1 |
Pretax Income | -93.3 | 46.6 | 106.3 | -30.9 | -62.7 |
Income Tax Expense | -22.6 | 20.2 | -20.7 | 0.8 | 0.7 |
Earnings From Continuing Operations | -70.7 | 26.4 | 127 | -31.7 | -63.4 |
Net Income to Company | -70.7 | 26.4 | 127 | -31.7 | -63.4 |
Net Income | -70.7 | 26.4 | 127 | -31.7 | -63.4 |
Net Income to Common | -70.7 | 26.4 | 127 | -31.7 | -63.4 |
Net Income Growth | - | -79.21% | - | - | - |
Shares Outstanding (Basic) | 40 | 40 | 40 | 40 | 40 |
Shares Outstanding (Diluted) | 40 | 40 | 40 | 40 | 40 |
EPS (Basic) | -1.79 | 0.67 | 3.21 | -0.80 | -1.60 |
EPS (Diluted) | -1.79 | 0.67 | 3.20 | -0.80 | -1.60 |
EPS Growth | - | -79.15% | - | - | - |
Free Cash Flow | -156.5 | 32.2 | -36.1 | -69.8 | 15.6 |
Free Cash Flow Per Share | -3.96 | 0.81 | -0.91 | -1.76 | 0.39 |
Dividend Per Share | 0.040 | 0.040 | 0.040 | - | 0.040 |
Gross Margin | 10.71% | 30.82% | 40.94% | 24.20% | 15.65% |
Operating Margin | -8.71% | 11.95% | 17.05% | -3.91% | -9.87% |
Profit Margin | -10.90% | 3.64% | 18.55% | -6.14% | -12.30% |
Free Cash Flow Margin | -24.12% | 4.43% | -5.27% | -13.53% | 3.03% |
EBITDA | -24.4 | 120.7 | 147.1 | 10.4 | -24.8 |
EBITDA Margin | -3.76% | 16.62% | 21.49% | 2.02% | -4.81% |
D&A For EBITDA | 32.1 | 33.9 | 30.4 | 30.6 | 26.1 |
EBIT | -56.5 | 86.8 | 116.7 | -20.2 | -50.9 |
EBIT Margin | -8.71% | 11.95% | 17.05% | -3.91% | -9.87% |
Effective Tax Rate | - | 43.35% | - | - | - |